Hostname: page-component-586b7cd67f-vdxz6 Total loading time: 0 Render date: 2024-11-22T07:39:28.808Z Has data issue: false hasContentIssue false

Rapid and Sustained Response to a Single Dose of Sertraline in a Patient with Newly Emergent Depression During Varenicline-Assisted Smoking Cessation

Published online by Cambridge University Press:  07 November 2014

Xiaolei Yu Baran*
Affiliation:
Weill Cornell Medical College
John P. Docherty
Affiliation:
Weill Cornell Medical College
*
New York Presbyterian Hospital, Payne Whitney Westchester, White Plains, NY 10605; Tel: 914-997-4358, Fax:, 646-962-1998; E-mail:, [email protected].
Rights & Permissions [Opens in a new window]

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Letter to the Editor
Copyright
Copyright © Cambridge University Press 2010

References

REFERENCES

1.Covey, LS, Glassman, AH, Stetner, F. Major depression following smoking cessation. Am J Psychiatry. 1997;154:263265.Google Scholar
2.Tsoh, JY, Humfleet, GL, Muñoz, RF, Reus, VI, Hartz, DT, Hall, SM. Development of major depression after treatment for smoking cessation. Am J Psychiatry. 2000;157:368374.Google Scholar
3.Glassman, AH, Heizer, JE, Covey, LS, et al.Smoking, smoking cessation, and major depression. JAMA. 1990;264:15461549.CrossRefGoogle ScholarPubMed
4.Hall, SM, Muñoz, RF, Reus, VI, Sees, KL. Nicotine, negative affect, and depression. J Consult Clin Psychol. 1993;61:761767.Google Scholar
5.Rollerna, H, Hajós, M, Seymour, PA, et al.Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition. Biochem Pharmacol. 2009;78:813824.Google Scholar
6.Kasliwal, R, Wilton, LV, Shakir, SA. Safety and drug utilization profile of varenicline as used in general practice in England: Interim results from a prescription-event monitoring study. Drug Saf. 2009;32:499507.CrossRefGoogle ScholarPubMed
7.Imperato, AA, Mulas, A, Di Chiara, G: Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur J Pharmacol. 1986;132:337338.Google Scholar
8.Grosshans, M, Mutschier, J, Hermann, D, Mann, K, Diehl, A. Reduced affective symptoms during tobacco dependence treatment with varenicline. Addiction. 2009;104:859861.Google Scholar
9.Philip, NS, Carpenter, LL, Tyrka, AR, Whiteley, LB, Price, LH. Varenicline augmentation in depressed smokers: an 8-week, open-label study. J Clin Psychiatry. 2009;70:10261031.Google Scholar
10.Popkin, MK. Exacerbation of recurrent depression as a result of treatment with varenicline. Am J Psychiatry. 2008:165:774.Google Scholar
11.Plrmoradi, P, Roshan, S, Nadeem, SS. Neuropsychiatrie disturbance after initiation of varenicline in a patient with a history of alcohol abuse and major depression. Am J Health Syst Pharm. 2008;65:16241626.CrossRefGoogle Scholar
12.FDA Drug Safety Newsletter. http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm169988.htm. Accessed: February 11, 2010.Google Scholar
13.Lyon, GJ. Possible varenicline-induced paranoia and irritability in a patient with major depressive disorder, borderline personality disorder, and methamphetamine abuse in remission. J Clin Psychopharmacol. 2008;28:720721.CrossRefGoogle Scholar
14.Pumariega, AJ, Nelson, R, Rotenberg, L. Varenicline-induced mixed mood and psychotic episode in a patient with a past history of depression. CNS Spectr. 2008;13:511514.Google Scholar
15.Kohen, I, Kremen, N. Varenicline-induced manic episode in a patient with bipolar disorder. Am J Psychiatry. 2007;164:12691270.Google Scholar
16.Gunnell, D, Irvine, D, Wise, L, Davies, C, Martin, RM. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ. 2009;339:b3805.Google Scholar
17.Foulds, J. The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline. Int J Clin Pract. 2006;60:571576.Google Scholar
18.Andreasen, JTOlsen, GM, Wiborg, O, Redrobe, JP. Antidepressant-like effects of nicotinic acetylcholine receptor antagonists, but not agonists, in the mouse forced swim and mouse tail suspension tests. J Psychopharmacol. 2009;23:797804.Google Scholar
19.Rollerna, H, Coe, JW, Chambers, LK, Hurst, RS, Stahl, SM, Williams, KE. Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. Trends Pharmacol Sci. 2007;28:316–235.Google Scholar
20.Rollerna, H, Guanowsky, VMineur, YS, et al.Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect. Eur J Pharmacol. 2009;605:114116.Google Scholar
21.Patterson, F, Jepson, C, Strasser, AA, et al.Varenicline improves mood and cognition during smoking abstinence. Biol Psychiatry. 2009;65:144149.CrossRefGoogle ScholarPubMed
22.Philip, NS, Carpenter, LL, Tyrka, AR, Whiteley, LB, Price, LH. Varenicline augmentation in depressed smokers: an 8-week, open-label study. J Clin Psychiatry. 2009;70:10261031.Google Scholar
23.Zarate, CA Jr, Singh, JB, Carlson, PJ, et al.A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856864.CrossRefGoogle ScholarPubMed
24.Daamen, MJ, Brown, WA. Single-dose fluoxetine in management of premenstrual syndrome. J Clin Psychiatry. 1992;53:210211.Google Scholar
25.Ahrens, T, Frankhauser, P, Lederbogen, F, Deuschle, M. Effect of single-dose sertraline on the hypothalamus-pituitary-adrenal system, autonomic nervous system, and platelet function. J Clin Psychopharmacol. 2007;27:602606.CrossRefGoogle ScholarPubMed
26.Alhatem, F, Black, JE. Varenicline-induced mania in a bipolar patient. Clin Neuropharmacol. 2009;32:117118.Google Scholar
27.Liu, ME, Tsai, SJ, Yang, ST. Varenicline-induced mixed mood and psychotic episode in a patient with schizoaffective disorder. CNS Spectr. 2009;14:346.Google Scholar